Halozyme Therapeutics, Inc. (BIT:1HALO)
Italy · Delayed Price · Currency is EUR | Market Cap | 9.67B +48.7% |
| Revenue (ttm) | 1.46B +41.2% |
| Net Income | 362.02M -25.8% |
| EPS | 2.96 -22.5% |
| Shares Out | n/a |
| PE Ratio | 26.72 |
| Forward PE | 9.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 86.44 |
| Day's Range | n/a |
| 52-Week Range | 51.28 - 89.64 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Halozyme Therapeutics
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) admini... [Read more]
Financial Performance
In 2025, Halozyme Therapeutics's revenue was $1.40 billion, an increase of 37.55% compared to the previous year's $1.02 billion. Earnings were $316.89 million, a decrease of -28.64%.
Financial numbers in USD Financial StatementsNews
Halozyme Therapeutics Earnings Call Transcript: Q2 2026
Record Q2 results featured 48% revenue growth, driven by robust ENHANZE royalties and new deals. Guidance for 2026 was raised, with strong momentum from both established and newly launched products, and significant expansion into ADC and nucleic acid modalities.
Halozyme Therapeutics Earnings release: Q2 2026
Halozyme Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Halozyme Therapeutics Quarterly report: Q2 2026
Halozyme Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Halozyme Therapeutics Slides: Q2 2026
Halozyme Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
Total Revenue Increased 48% YOY to $481 million Royalty Revenue Increased 50% YOY to $308 million Raises 2026 Financial Guidance Ranges: Total Revenue of $1.835 - $1.910 billion, YOY Growth of 31% - 3...
Halozyme to Report Second Quarter 2026 Financial and Operating Results
SAN DIEGO, July 23, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on Thursday, Au...
Halozyme's Partnerships, Earnings Growth See Shares Near All-Time Highs
Halozyme Therapeutics, Inc. (HALO) shares gain 539% since first Big Money outlier inflow signal in March 2014.
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targets SAN DIEGO, July 20, 2026 /PRNewsw...
Halozyme Appoints David Ramsay as President Drug Delivery
SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, effective ...
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based ...
Halozyme Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw 42% revenue and 43% royalty growth, driven by ENHANZE-enabled products and strong partner launches. Guidance for 2026–28 was reaffirmed, with new collaborations, a $1B buyback, and robust pipeline momentum supporting long-term growth.
Halozyme Therapeutics Earnings release: Q1 2026
Halozyme Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Halozyme Therapeutics Quarterly report: Q1 2026
Halozyme Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Halozyme Therapeutics Slides: Q1 2026
Halozyme Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 11, 2026.
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
Announcing New $1 billion Share Repurchase Program Projecting to Buy Back at Least $400 million in 2026 Total Revenue Increased 42% YOY to $377 million Royalty Revenue Increased 43% YOY to $241 millio...
Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
Marks first ENHANZE ® agreement to include ADC targets Collaboration also includes option for additional future targets First clinical trial projected to initiate in 2026 SAN DIEGO, May 7, 2026 /PRNew...
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional target SAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Na...
Halozyme Therapeutics Transcript: AGM 2026
The meeting approved all proposals, including director elections and auditor ratification. Strong financial performance and pipeline expansion were highlighted, with new agreements and acquisitions positioning for future growth. Shareholder Q&A addressed capital allocation and ongoing litigation.
Halozyme to Report First Quarter 2026 Financial and Operating Results
SAN DIEGO, April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its first quarter 2026 financial and operating results on Monday, May ...
Halozyme Appoints Darren Snellgrove as Chief Financial Officer
SAN DIEGO, April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of Darren Snellgrove as Chief Financial Officer, effe...
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
SAN DIEGO, April 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a g...
Halozyme Therapeutics Proxy statement: Proxy filing
Halozyme Therapeutics filed a proxy statement on March 23, 2026, providing details for shareholder voting and corporate governance matters.
Halozyme Therapeutics Proxy statement: Proxy filing
Halozyme Therapeutics filed a proxy statement on March 23, 2026, providing details for shareholder voting and corporate governance matters.
Halozyme Appoints David Ramsay as Interim Chief Financial Officer
SAN DIEGO, March 12, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced that David Ramsay has been appointed Interim Chief Financial Officer ...